

**STERLING BIOTECH LIMITED**

Registered Office : 43, Atlanta, Nariman Point, Mumbai – 400 021.

**UNAUDITED FINANCIAL RESULTS (PROVISIONAL)  
FOR THE FIRST QUARTER ENDED 31<sup>ST</sup> MARCH, 2007**

Sr. No	Particulars	Rs. In Lacs		
		Quarter ended 31-03-2007 (Unaudited)	Corresponding Quarter ended 31-03-2006 (Unaudited)	For the year ended 31-12-2006 (Audited)
1	Net Sales	17,403.29	13,387.70	60,585.36
2	Other Income	232.03	81.88	504.52
3	Total Income	17,635.32	13,469.58	61,089.88
4	Total Expenditure	9,178.30	7,178.64	31,865.14
	a) (Increase)/Decrease in Stocks	(414.78)	(231.04)	(1,268.81)
	b) Consumption of raw materials	5,951.53	4,603.22	20,997.60
	c) Staff Cost	458.86	369.31	1,626.88
	d) Other Expenditure	3,182.69	2,437.15	10,509.47
5	Interest	1,053.51	1,028.16	4,116.70
6.	Gross Profit	7,403.50	5,262.78	25,108.04
7	Depreciation	1,915.73	1,234.06	6,202.55
8	Profit before Extraordinary Expenditure and Tax	5,487.78	4,028.72	18,905.49
9	Extraordinary Expenditure (Non Recurring)	161.29	161.29	645.14
10	Profit after Extraordinary Expenditure but before tax	5,326.49	3,867.43	18,260.35
11	Provision for Current Tax	565.00	320.00	1,900.00
12	Provision for Deferred Tax	950.00	515.00	2,850.00
13.	Provision for Fringe Benefit Tax	5.87	8.89	30.75
14	Net Profit	3,805.62	3,023.54	13,479.60
15	Prior Year Adjustment	0.00	0.00	128.99
16	Profit available for appropriation	3,805.62	3,023.54	13,350.61
17	Paid-up Equity Capital (Face Value Rs. 1/- per share)	2,259.05	2,212.49	2,223.48
18	Reserves Excluding Revaluation Reserves			99,048.80
19	Basic EPS (Not Annualised) on F.V. Rs.1/-	1.68	1.37	6.00
20	Diluted EPS (Not Annualised) on F.V. Rs.1/-	1.68	1.37	6.00
21	Aggregate of Public Shareholding			
	a) No. of Shares (F.V. of Re. 1/-)	147,931,886	151,026,858	152,125,969
	b) Percentage of Shareholdings	65.48	68.26%	68.42%

1. The company's operations fall under single segment hence segment reporting as defined in Accounting Standard 17 is not applicable.
2. The above financial results were reviewed by the audit committee and taken on record by the Board of Directors at its meeting held on 19<sup>th</sup> April, 2007.
3. The Statutory Auditors have carried out a limited review of the financial results for the quarter ended 31<sup>st</sup> March, 2007.
4. During the quarter, the company had commenced production of CoQ10 at its manufacturing facilities at Masar, Dist. Baroda, Gujarat .
5. During the quarter, the company had issued 3,556,631 equity shares out of conversion of FCCBs.
6. The number of investor complaints for the quarter ended 31<sup>st</sup> March, 2007 were :  
Opening – 11, Received - 40, Disposed off - 44, and Balance - 7.

For and On Behalf of  
**STERLING BIOTECH LIMITED**

Place : Mumbai  
Date : 19<sup>th</sup> April, 2007

**Chetan J. Sandesara**  
**Director**